Immunic (NASDAQ:IMUX) Given New $4.00 Price Target at D. Boral Capital

Immunic (NASDAQ:IMUX) had its price objective cut by investment analysts at D. Boral Capital from $8.00 to $4.00 in a research note issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. D. Boral Capital’s target price would suggest a potential upside of 359.72% from the stock’s current price.

Other analysts also recently issued research reports about the company. Brookline Capital Acquisition raised Immunic to a “strong-buy” rating in a research note on Tuesday, February 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Immunic in a report on Monday, December 29th. Chardan Capital upgraded Immunic to a “strong-buy” rating in a report on Wednesday, November 19th. Roth Mkm started coverage on Immunic in a research report on Friday, November 7th. They issued a “buy” rating and a $3.00 price objective for the company. Finally, LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a research note on Thursday, October 16th. Four research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $6.60.

Immunic Price Performance

Immunic stock opened at $0.87 on Friday. Immunic has a fifty-two week low of $0.51 and a fifty-two week high of $1.39. The firm has a market capitalization of $104.66 million, a price-to-earnings ratio of -1.05 and a beta of 1.58. The company’s 50 day simple moving average is $0.63 and its 200 day simple moving average is $0.76.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. As a group, analysts predict that Immunic will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Immunic

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Qube Research & Technologies Ltd acquired a new position in shares of Immunic during the 3rd quarter worth about $29,000. Two Sigma Investments LP bought a new position in Immunic in the third quarter valued at approximately $52,000. HB Wealth Management LLC acquired a new position in shares of Immunic during the 3rd quarter worth approximately $81,000. Virtu Financial LLC bought a new stake in shares of Immunic during the 3rd quarter worth approximately $99,000. Finally, Jane Street Group LLC raised its stake in shares of Immunic by 46.8% during the 4th quarter. Jane Street Group LLC now owns 286,677 shares of the company’s stock worth $153,000 after purchasing an additional 91,346 shares in the last quarter. 51.82% of the stock is currently owned by institutional investors and hedge funds.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.